AnaptysBio Inc/ US0327241065 /
5/17/2024 10:00:00 PM | Chg. -0.4000 | Volume | Bid10:11:15 PM | Ask10:11:15 PM | High | Low |
---|---|---|---|---|---|---|
25.0700USD | -1.57% | 190,839 Turnover: 3.59 mill. |
15.0000Bid Size: 100 | 39.7200Ask Size: 200 | 25.4300 | 24.5100 |
GlobeNewswire
5/9
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/9
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...
GlobeNewswire
5/9
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...
GlobeNewswire
3/26
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Cl...
GlobeNewswire
3/11
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
2/29
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
GlobeNewswire
11/27/2023
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Po...
GlobeNewswire
11/11/2023
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AnaptysBio, Inc. (NASDAQ: ANAB) and En...
GlobeNewswire
11/7/2023
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into AnaptysBio, Inc.; Urges AnaptysBio’s...
GlobeNewswire
11/2/2023
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
10/11/2023
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
GlobeNewswire
10/9/2023
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 2...
GlobeNewswire
10/9/2023
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Genera...
GlobeNewswire
9/18/2023
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
GlobeNewswire
9/12/2023
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
GlobeNewswire
3/14/2022
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne